• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".

作者信息

Semmler Georg, Balcar Lorenz, Mandorfer Mattias

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

出版信息

Clin Mol Hepatol. 2025 Apr;31(2):615-619. doi: 10.3350/cmh.2024.1180. Epub 2025 Jan 6.

DOI:10.3350/cmh.2024.1180
PMID:39761960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12016598/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1d/12016598/1bc40c5920e4/cmh-2024-1180f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1d/12016598/1bc40c5920e4/cmh-2024-1180f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1d/12016598/1bc40c5920e4/cmh-2024-1180f1.jpg

相似文献

1
Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".经颈静脉肝内门体分流术治疗全身炎症：关于“经颈静脉肝内门体分流术置入可导致失代偿期肝硬化患者全身炎症持续逆转”的社论
Clin Mol Hepatol. 2025 Apr;31(2):615-619. doi: 10.3350/cmh.2024.1180. Epub 2025 Jan 6.
2
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis.经颈静脉肝内门体分流术可使失代偿期肝硬化患者的全身炎症持续逆转。
Clin Mol Hepatol. 2025 Jan;31(1):240-255. doi: 10.3350/cmh.2024.0587. Epub 2024 Nov 21.
3
TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".经颈静脉肝内门体分流术（TIPS）置入与全身炎症：降低门静脉压力会为时过晚吗？致关于“经颈静脉肝内门体分流术置入可导致失代偿期肝硬化患者全身炎症持续逆转”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e176-e179. doi: 10.3350/cmh.2025.0135. Epub 2025 Feb 10.
4
Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.经颈静脉肝内门体分流术治疗肝硬化患者：适应证和 2020 年经颈静脉肝内门体分流术相关并发症。
United European Gastroenterol J. 2021 Mar;9(2):203-208. doi: 10.1177/2050640620952637. Epub 2021 Feb 23.
5
Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.经颈静脉肝内门体分流术和 Alfapump®系统治疗肝硬化难治性腹水：结局和并发症。
United European Gastroenterol J. 2020 Oct;8(8):961-969. doi: 10.1177/2050640620938525. Epub 2020 Jun 26.
6
Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis.超声心动图显示舒张功能障碍不能预测肝硬化经颈静脉肝内门体分流支架植入术后患者的生存。
Aliment Pharmacol Ther. 2019 Mar;49(6):797-806. doi: 10.1111/apt.15164. Epub 2019 Feb 17.
7
Transjugular intrahepatic portosystemic shunt in decompensated cirrhotic patients in a tertiary hospital in southern Brazil.巴西南部一家三级医院失代偿期肝硬化患者经颈静脉肝内门体分流术。
Rev Assoc Med Bras (1992). 2023 Apr 14;69(4):e20220944. doi: 10.1590/1806-9282.20220944. eCollection 2023.
8
Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?经颈静脉肝内门体分流术后新发肝细胞癌会增加吗？
United European Gastroenterol J. 2018 Apr;6(3):413-421. doi: 10.1177/2050640617732886. Epub 2017 Sep 20.
9
Transjugular intrahepatic portosystemic shunt for recompensating decompensated cirrhosis?经颈静脉肝内门体分流术治疗失代偿期肝硬化？
World J Gastroenterol. 2024 May 28;30(20):2621-2623. doi: 10.3748/wjg.v30.i20.2621.
10
Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites.经颈静脉肝内门体分流术对肝硬化难治性腹水患者血浆内皮素-1和大内皮素-1的影响
J Hepatol. 1996 Nov;25(5):700-6. doi: 10.1016/s0168-8278(96)80241-8.

引用本文的文献

1
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".经颈静脉肝内门体分流术后全身炎症反应的减轻：肝脏仍有希望：对关于“经颈静脉肝内门体分流术可使失代偿期肝硬化患者的全身炎症反应持续逆转”的通信的回复
Clin Mol Hepatol. 2025 Apr;31(2):e224-e225. doi: 10.3350/cmh.2025.0149. Epub 2025 Feb 17.
2
TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".经颈静脉肝内门体分流术（TIPS）置入与全身炎症：降低门静脉压力会为时过晚吗？致关于“经颈静脉肝内门体分流术置入可导致失代偿期肝硬化患者全身炎症持续逆转”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e176-e179. doi: 10.3350/cmh.2025.0135. Epub 2025 Feb 10.

本文引用的文献

1
Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis.经颈静脉肝内门体分流术后白细胞介素-6水平降低可预测失代偿期肝硬化的预后。
JHEP Rep. 2024 Dec 18;7(4):101308. doi: 10.1016/j.jhepr.2024.101308. eCollection 2025 Apr.
2
Inflammation remains a dynamic component of portal hypertension in regressive alcohol-related cirrhosis.在酒精性退行性肝硬化中，炎症仍然是门静脉高压的一个动态组成部分。
United European Gastroenterol J. 2025 Apr;13(3):317-329. doi: 10.1002/ueg2.12643. Epub 2024 Dec 21.
3
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis.
经颈静脉肝内门体分流术可使失代偿期肝硬化患者的全身炎症持续逆转。
Clin Mol Hepatol. 2025 Jan;31(1):240-255. doi: 10.3350/cmh.2024.0587. Epub 2024 Nov 21.
4
Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding.确定肝硬化合并静脉曲张出血患者经颈静脉肝内门体分流术后门静脉压力梯度的最佳测量时机和血流动力学目标。
J Hepatol. 2025 Feb;82(2):245-257. doi: 10.1016/j.jhep.2024.08.007. Epub 2024 Aug 22.
5
Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.可溶性尿激酶型纤溶酶原激活物受体水平可预测接受经颈静脉肝内门体分流术的门静脉高压患者的生存率。
JHEP Rep. 2024 Mar 4;6(5):101054. doi: 10.1016/j.jhepr.2024.101054. eCollection 2024 May.
6
Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.近期在代偿期肝硬化和慢加急性肝衰竭（ACLF）的预防和治疗方面的进展，以及生物标志物的作用。
Gut. 2024 May 10;73(6):1015-1024. doi: 10.1136/gutjnl-2023-330584.
7
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.TIPS 通过个体患者数据分析荟萃分析预防肝硬化和门静脉高压患者的进一步失代偿并改善生存。
J Hepatol. 2023 Sep;79(3):692-703. doi: 10.1016/j.jhep.2023.04.028. Epub 2023 May 2.
8
Ascites and complications: getting to the root of the trouble.腹水及其并发症：探寻问题根源
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):124-127. doi: 10.21037/hbsn-22-625. Epub 2023 Jan 6.
9
Beta-blockers in the era of precision medicine in patients with cirrhosis.精准医学时代肝硬化患者使用β受体阻滞剂的情况
J Hepatol. 2023 Apr;78(4):866-872. doi: 10.1016/j.jhep.2022.12.005. Epub 2022 Dec 15.
10
Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis.全身炎症的严重程度是急性失代偿性肝硬化患者发生慢加急性肝衰竭和出血的主要预测指标。
J Hepatol. 2023 Feb;78(2):301-311. doi: 10.1016/j.jhep.2022.09.005. Epub 2022 Sep 21.